舒利迭治疗哮喘急性发作的疗效

Effect of Inhalation of Salmeterol Xinafoate and Fluticasone Propionate Powder in Acute Onset of Children with Asthma

目的观察哮喘急性发作期患儿吸入舒利迭对速效β2受体激动剂发挥快速缓解作用的影响。方法急性发作期哮喘患儿89例随机分为两组,治疗组39例,对照组50例。治疗组每天均按照缓解期分度分别予等效剂量的舒利迭,中度50/100μg,2次/d,重度50/100μg,3次/d;对照组给予布地奈德气雾剂,中度400μg/d,2次/d,重度800μg/d,2次/d;两组均予硫酸特布他林雾化液,5mg/d,分2次吸入,连用5d。观察喘息、咳嗽、肺部哮鸣音等改善情况。检测最大呼气量(PEF)。结果两组PEF占预计值百分比显著提高;两组喘憋、哮鸣音、湿音消失及住院时间均无显著差异(均P>0.05)。结论舒利迭在哮喘急性发作期并不因为其含有长效β2受体激动剂而影响速效β2受体激动剂发挥快速平喘作用。

Objective To observe influence of salrneterol xinafoate and fluticasone propionate powder applied in asthmatic exacerbated period on relieving efficacy of a fast - acting beta2 - agonist. Methods Eighty - nine children with asthma in exacerbated period were randomly assigned into two groups. Thirty - nine cases in treatment group inhaled salrneterol xinafoate and fluticasone propionate powder, compared with 50 case.s in control group treated with budesonide aerosol. Two groups were all given Bricanyl aerolised inhalation in same way at meanwhile. Results The improvement of peak expinatory flow in two groups was evident. The disappearing time of main symptoms and signs, the duration of staying in hospital of two groups were no difference （all P〈0.05）. Conclusion Salrneterol xinafoate and fluticasone propionate powder which contains long - acting beta2 - agonist does not affect relieving efficacy of a fast - acting beta2 - agonist in asthmatic exacerbated period.